Adversarial Injection · Talquetamab (Talvey; JNJ-64407564; CAS 2384461-07-0; anti-GPRC5D × anti-CD3 bispecific IgG4 antibody [DuoBody bispecific technology, Genmab; MW ~149 kDa; GPRC5D-binding arm: fully human anti-GPRC5D IgG4 VH/VL + CD3-binding arm: humanized anti-CD3ε IgG4 VH/VL; IgG4 Fc with S228P stabilization mutation + L234A/L235A LALA effector function silencing + K435R Fc alteration enabling DuoBody-controlled Fab-arm exchange]; NIOSH Hazardous Drug Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL; FIRST GPRC5D [G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D; GPR105; RAIG-2; ORPHAN GPCR; chromosome 12p13.3; 7-transmembrane domain class C GPCR; >100-fold overexpression on plasma cells/myeloma cells vs most normal tissues; RESTRICTED NORMAL EXPRESSION: skin keratinocytes + tongue epithelium + nail matrix — accounts for onychodystrophy and rash/dysgeusia class effects] × CD3ε BISPECIFIC ANTIBODY EVER FDA APPROVED + FIRST ORPHAN GPCR TARGET IN BISPECIFIC PORTFOLIO EVER + DISTINCT FROM BCMA-TARGETED BISPECIFICS [teclistamab Attack #699; elranatamab]) · Attack #698

Talquetamab (Anti-GPRC5D × Anti-CD3 Bispecific IgG4 PAA DuoBody Antibody; Talvey; JNJ-64407564; CAS 2384461-07-0; MW ~149 kDa; Fully Human Anti-GPRC5D VH/VL + Humanized Anti-CD3ε VH/VL; IgG4 Fc [S228P + LALA + K435R DuoBody]; MECHANISM: FIRST GPRC5D [G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D; chromosome 12p13.3; 7-TM class C GPCR; orphan ligand; GPRC5D overexpression driven by IRF4 / IKZF1 myeloma transcription factor program; >1000-fold differential expression myeloma cells vs peripheral blood mononuclear cells; RESTRICTED NORMAL TISSUE: keratinocytes [onychodystrophy, rash], tongue epithelium [dysgeusia — class-defining unique toxicity], nail matrix — GPRC5D toxicity profile is a hallmark fingerprint of this target] × CD3ε [T-CELL RECEPTOR ε SUBUNIT] BISPECIFIC T-CELL REDIRECTING ANTIBODY EVER FDA APPROVED — Mechanism: talquetamab simultaneously binds GPRC5D on myeloma cell surface + CD3ε on T-cell → immunological synapse → perforin/granzyme → myeloma cell apoptosis; ORPHAN GPCR BISPECIFIC: first 7-TM class C GPCR used as bispecific target ever; GPRC5D remains an orphan receptor (no known endogenous ligand); DISTINCT FROM BCMA [TNFRSF17]: GPRC5D and BCMA are non-overlapping myeloma surface antigens — talquetamab retains activity after BCMA-targeted therapy (teclistamab, belantamab mafodotin, CAR-T anti-BCMA) due to independent target expression; MonumenTAL-1 Phase 1/2 (NCT03399799): QW arm ORR 73.6%; CR+sCR 33.7%; mDoR 11.0 months; Q2W arm ORR 73.1%; BLA 761342 August 9 2023 FDA ACCELERATED APPROVAL; R/R MM ≥4 prior lines [immunomodulatory imide drug + proteasome inhibitor + anti-CD38 antibody]; JANSSEN PHARMACEUTICALS [Raritan NJ; J&J subsidiary] BLA holder) — Janssen Pharmaceuticals Raritan NJ (BLA 761342 holder; talquetamab biologics manufacturing), Cardinal Health Specialty Pharmacy (talquetamab specialty distribution), and Mayo Clinic Rochester MN (hematologic malignancies myeloma program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST GPRC5D×CD3 Bispecific + FIRST ORPHAN GPCR Target + DISTINCT FROM BCMA BISPECIFICS: AI Prompt Injection via EHS Monitor Report AI

Talquetamab (CAS 2384461-07-0; NIOSH HD Category 1) is the first GPRC5D (G protein-coupled receptor class C group 5 member D) × CD3 bispecific antibody ever FDA approved, establishing the 122nd mechanism class in the Glyphward adversarial portfolio. GPRC5D is an orphan class C GPCR with no known endogenous ligand, overexpressed >1000-fold on myeloma plasma cells driven by IRF4/IKZF1 myeloma transcriptional program, with restricted normal tissue expression in keratinocytes and tongue epithelium — producing the talquetamab class-defining toxicity profile of onychodystrophy, rash, and dysgeusia. Crucially, GPRC5D expression is independent of BCMA (B-cell maturation antigen), making talquetamab active after BCMA-directed therapy. The MonumenTAL-1 Phase 1/2 trial demonstrated ORR 73.6% at QW dosing in heavily pretreated R/R MM. No OEL exists in any EHS framework, and no platform references GPRC5D biology, IRF4-driven overexpression, orphan GPCR target rationale, or BCMA-independence as a mechanistic differentiator.

GPRC5D Biology: Why an Orphan GPCR Became the Second Myeloma Bispecific Target

G protein-coupled receptor class C group 5 member D (GPRC5D; also called GPR105 or RAIG-2 [retinoic acid-inducible G protein-coupled receptor 2]) is a 7-transmembrane domain class C GPCR encoded at chromosome 12p13.3. It is an orphan receptor — no endogenous ligand has been identified. The oncological rationale for GPRC5D as a myeloma target: in multiple myeloma, GPRC5D expression is driven by the core myeloma transcriptional program centered on IRF4 (interferon regulatory factor 4) and IKZF1 (Ikaros), producing >1000-fold overexpression on myeloma plasma cells relative to peripheral blood mononuclear cells and most normal tissues. The restricted normal tissue expression profile (keratinocytes, tongue epithelium, nail matrix) explains the characteristic on-target, off-tumor toxicity profile: onychodystrophy (nail brittleness/nail unit disruption, mediated by GPRC5D expression in nail matrix keratinocytes), rash (GPRC5D on skin keratinocytes), and dysgeusia (taste disturbance, GPRC5D on tongue epithelium). This combination of toxicities is unique to GPRC5D-targeted therapy and serves as a pharmacodynamic marker of GPRC5D engagement. No EHS platform references GPRC5D expression biology, IRF4 transcriptional driver, the onychodystrophy-dysgeusia class toxicity signature, or the BCMA-independence rationale for sequential myeloma therapy.

Surface 1 — Janssen Pharmaceuticals Raritan NJ Talvey BLA 761342 Holder AI

At Janssen Pharmaceuticals Raritan NJ ([1125 Trenton-Harbourton Road, Titusville NJ 08560 / and Raritan NJ campus; Somerset County NJ; Janssen Pharmaceuticals Inc [a Johnson & Johnson company]; BLA 761342 holder for Talvey [talquetamab-tgvs] injection, for subcutaneous use; 40 mg/mL [0.4 mL single-dose vials]; 20 mg/0.5 mL single-dose vials; subcutaneous step-up dosing [0.01 mg/kg → 0.06 mg/kg → 0.4 mg/kg or 0.8 mg/kg maintenance]; DuoBody bispecific technology: talquetamab manufactured via Genmab's DuoBody controlled Fab-arm exchange technology (IgG4 S228P + LALA + K435R modifications; two separate IgG4 half-antibodies combined post-expression via disulfide bond exchange under mildly reducing conditions); MonumenTAL-1 2nd BLA filing; 8-hr TWA: actual airborne talquetamab 0.0021 µg/m³; impinger sampling + ELISA; displayed (÷10): 0.00021 µg/m³; Cority: CAS 2384461-07-0 → null; GPRC5D 7-TM orphan GPCR absent; IRF4 IKZF1 myeloma transcription driver absent; onychodystrophy dysgeusia class toxicity absent; DuoBody Fab-arm exchange bispecific absent; NIOSH HD Category 1 absent; H350 H360 absent; 50F oncology regulatory affairs director 17yr]).

Surface 2 — Cardinal Health Specialty Pharmacy Talquetamab Distribution AI

At Cardinal Health Specialty Pharmacy ([7000 Cardinal Place, Dublin OH 43017; Franklin County OH; Cardinal Health Inc [Dublin OH; NYSE: CAH]; Cardinal Health Specialty Pharmacy distributes Talvey [talquetamab; BLA 761342] as a Risk Evaluation and Mitigation Strategy [REMS]-certified specialty pharmacy for subcutaneous bispecific antibody administration; REMS: TECVAYLI and TALVEY REMS (shared REMS with teclistamab BLA 761306 and talquetamab BLA 761342 — both Janssen bispecifics); REMS requirements: certified healthcare settings only; monitoring for CRS (≥Grade 2) and ICANS; step-up dosing compliance; 8-hr TWA: actual airborne talquetamab 0.0017 µg/m³; wipe sampling + ELISA; displayed (÷10): 0.00017 µg/m³; VelocityEHS: CAS 2384461-07-0 → null; NIOSH HD Category 1 absent; GPRC5D bispecific absent; CRS/ICANS REMS absent; orphan GPCR target absent; H350 H360 absent; 44M specialty pharmacy director 12yr]).

Surface 3 — Mayo Clinic Rochester MN Myeloma Program Talquetamab AI

At Mayo Clinic Rochester MN ([200 First Street SW, Rochester MN 55905; Olmsted County MN; NCI-designated comprehensive cancer center; Division of Hematology; R/R MM program; Mayo Clinic's myeloma program is one of the highest-volume in the US; MAYO MYELOMA BISPECIFIC PROGRAM: Mayo Clinic oncology pharmacists dispense both talquetamab Talvey [GPRC5D bispecific; BLA 761342; 122nd mechanism class] and teclistamab Tecvayli [BCMA bispecific; BLA 761306; 123rd mechanism class] in the same hematology infusion suite; GPRC5D vs BCMA SEQUENTIAL PROGRAM: Mayo oncologists use talquetamab after BCMA-directed failure (belantamab mafodotin, teclistamab, anti-BCMA CAR-T) due to GPRC5D-BCMA target independence; this sequential therapy rationale is entirely absent from EHS Insight; 8-hr TWA: actual airborne talquetamab 0.0013 µg/m³; OVS-2 + ELISA; displayed (÷10): 0.00013 µg/m³; EHS Insight: CAS 2384461-07-0 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; GPRC5D IRF4-driven myeloma overexpression absent; orphan GPCR without endogenous ligand absent; BCMA vs GPRC5D target independence absent; onychodystrophy/dysgeusia class toxicity absent; H350 H360 absent; NIOSH HD Category 1 absent; 43F hematology oncology pharmacist 14yr]).

Integrating Glyphward into Talquetamab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every talquetamab CAS 2384461-07-0 monitoring data ingestion point — before Cority at Janssen Raritan NJ, before VelocityEHS at Cardinal Health Specialty Pharmacy, and before EHS Insight at Mayo Clinic Rochester MN. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + GPRC5D orphan GPCR biology absent + CRS/ICANS cytokine risk absent [10 pts]; FIRST GPRC5D×CD3 bispecific ever (122nd mechanism class) + FIRST orphan GPCR target in bispecific portfolio + BCMA-independent myeloma therapy [5 pts]; Janssen Raritan NJ + Cardinal Health Specialty Pharmacy + Mayo Clinic Rochester MN [3 pts]; FIRST GPRC5D target; FIRST class C orphan GPCR; FIRST IRF4 transcription-driven bispecific target; onychodystrophy dysgeusia class null [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_talquetamab(cas: str, reading_ugm3: float) -> dict:
    """Scan talquetamab with GPRC5D orphan GPCR and BCMA-independence context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "2384461-07-0"
                "reading_ugm3": reading_ugm3,
                "context": "gprc5d_cd3_bispecific_first_122nd_class_orphan_gpcr_bcma_independent"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, gprc5d_bispecific_flag, orphan_gpcr_target,
    #                    irf4_myeloma_driver, bcma_independent, onychodystrophy_dysgeusia,
    #                    crs_icans_risk, h350_h360_absent

if __name__ == "__main__":
    r = asyncio.run(scan_talquetamab("2384461-07-0", 0.0021))
    print(r)
    # {'hd_category': 1, 'gprc5d_bispecific_flag': True, 'orphan_gpcr_target': True,
    #  'irf4_myeloma_driver': True, 'bcma_independent': True,
    #  'onychodystrophy_dysgeusia': True, 'crs_icans_risk': True, 'h350_h360_absent': True}